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http://www.biomedcentral.com/1755-8794/7/44RESEARCH ARTICLE Open AccessMeasurement of absolute copy number variation
reveals association with essential hypertension
Francine Z Marques1, Priscilla R Prestes1, Leonardo B Pinheiro2, Katrina Scurrah3, Kerry R Emslie2,
Maciej Tomaszewski4, Stephen B Harrap3 and Fadi J Charchar1*Abstract
Background: The role of copy number variation (CNV) has been poorly explored in essential hypertension in part
due to technical difficulties in accurately assessing absolute numbers of DNA copies. Droplet digital PCR (ddPCR)
provides a powerful new approach to CNV quantitation. The aim of our study was to investigate whether CNVs
located in regions previously associated with blood pressure (BP) variation in genome-wide association studies
(GWAS) were associated with essential hypertension by the use of ddPCR.
Methods: Using a “power of extreme” approach, we quantified nucleic acids using ddPCR in white subjects from
the Victorian Family Heart Study with extremely high (n = 96) and low (n = 92) SBP, providing power equivalent to
1714 subjects selected at random.
Results: A deletion of the CNVs esv27061 and esv2757747 on chromosome 1p13.2 was significantly more prevalent
in extreme high BP subjects after adjustment for age, body mass index and sex (12.6% vs. 2.2%; P = 0.013).
Conclusions: Our data suggests that CNVs within regions identified in previous GWAS may play a role in human
essential hypertension.
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Essential hypertension is a multifactorial condition with
a substantial contribution attributed to heritable genetic
factors [1]. Unravelling the genetic predisposition to high
blood pressure (BP), however, has proven challenging,
mostly due to phenotypic heterogeneity [2]. Single nu-
cleotide polymorphisms (SNPs) have been the most
studied type of polymorphism in essential hypertension,
particularly in genome-wide association (GWA) studies [2].
A meta-analysis of GWA studies in 200,000 individuals of
European ancestry found that 29 SNPs at 28 loci were asso-
ciated with changes in systolic blood pressure (SBP), dia-
stolic blood pressure (DBP) and/or hypertension [3]. A
majority of these SNPs, however, are not causal being mere
proxies of genuinely functional alleles in the vicinity.
In contrast to SNPs, copy number variations (CNVs)
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unless otherwise stated.translocations and inversions of genomic material vary-
ing from 1 kilobase to several megabases [4,5]. CNVs
cover about 12% of the human genome [6] and import-
antly, half of them overlap with protein-coding regions
[7]. In humans 85–95% of CNVs are associated with
changes in expression of the affected genes [8]. There
have been very few studies on the association between
CNVs and essential hypertension [3,9]. One reason for this
paucity of data is that most of the techniques available up
to now, such as real-time quantitative PCR (qPCR) [10],
have proven unreliable, as they do not measure the abso-
lute number of copies, a prerequisite for meaningful ana-
lyses of association between CNVs and BP variation.
The combined use of limited dilutions, Poisson distri-
bution and PCR was first described in 1992 [11], allow-
ing the measurement of the absolute numbers of nucleic
acid in a sample, later called digital PCR (dPCR) [12]. In
this study, we took advantage of a new system for dPCR
analysis, the droplet digital PCR (ddPCR) [13]. High pre-
cision in copy number measurements can be achieved
due to the large number of droplets analysed (>10,000)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is more reliable and precise compared to other techniques
available [14,15].
The hypothesis of our study is that changes in genomic
copy number may be associated with essential hyperten-
sion and/or BP variation but may have been missed in pre-
vious studies [9]. We first identified all the CNVs located
in regions associated with BP/hypertension in the previous
GWA meta-analysis. We then quantified these CNVs by
high fidelity ddPCR to determine whether they are associ-
ated with hypertension. As a robust approach, we used the
‘power of extreme’ approach method [16,17] to enrich for
rare but potent variants that could explain high BP.Table 1 Single nucleotide polymorphisms associated with
high blood pressure located in regions containing copy
number variation (Build hg19, based on the Database for
Genomic Variants and UCSC Genome Browser, search
performed on 28 May 2014)
SNP ID CNV ID Genomic landmark Assay ID
rs2932538 esv27061 chr1:112,692,629-113,246,263 Hs01327571
esv2757747* chr1:113,157,135-116,741,372 Hs01327571
rs7129220 nsv483076 chr11:10,193,294-10,352,897 Hs04399968
rs17608766 dgv976e1 chr17:44,083,914-45,277,333 Hs00313538
esv2656635 chr17:44,281,452-45,168,501 Hs00313538
nsv908562 chr17:44,828,931-45,102,413 Hs00313538
dgv986e1 chr17:44,971,360-45,277,333 Hs00313538
rs1327235 dgv1306e1 chr20:10,892,138-11,116,725 Hs03126928
Footnote: SNP, single nucleotide polymorphism; ID, identification; CNV, copy
number variation.
*essv21692 is described in the UCSC Genome Browser, however, it is a
supporting structural variant as a single individual. Therefore, according to
NCBI, essv21962 is a part of the CNV esv2757747.Methods
Participants
The participants included in this study were selected from
the Victorian Family Heart Study (VFHS), a healthy
population-based cohort of European-descendants col-
lected in Melbourne, Australia, to specifically study the
family patterns in cardiovascular risk factors [18-21]. SBP
was estimated based in the average of 2 lying SBP values
and 2 standing SBP values. SBP and DBP for subjects on
antihypertensive treatment (53.1% of the high BP group)
were adjusted. Briefly, 10 mm Hg was added to systolic
blood pressure and 5 mm Hg to diastolic blood pressure,
as previously described [22,23]. In order to maximize the
statistical power and enrich for rare variants in the current
analysis, we selected a sex-matched sample of biologically
unrelated subjects. We selected 96 and 92 subjects from
the highest and lowest deciles for SBP in the VFHS, re-
spectively. This was done in consideration of a mean SBP
(122 mm Hg; SD: 14.3 mm Hg) in the VFHS, the mean
SBPs of the high (166 mm Hg; SD: 12.3 mm Hg) and low
(98 mm Hg; SD: 5.2 mm Hg) groups differed by ≈ 4.5 SDs.
This provides power equivalent to 1714 subjects selected
at random [22]. DNA was extracted from white blood
cells. All subjects gave informed consent and the study
was approved by the human research ethics committee at
the Alfred Hospital, Melbourne, Australia.
In order to investigate whether having differential num-
ber of copies would lead to differential gene expression, we
also genotyped forty Polish individuals of white European
ancestry from the Silesian Renal Tissue Bank (SRTB), col-
lected to study genetic aspects of human cardiovascular
disease. DNA samples were extracted from white blood
cells. Recruitment and phenotyping were as described
[24,25]. Diagnosis of hypertension was as stipulated for the
Silesian Hypertension Study. These subjects underwent
elective unilateral nephrectomy because of non-invasive
renal cancer. Samples from a pole of kidney unaffected by
the neoplastic process had RNA extracted for gene expres-
sion analyses. All subjects gave informed consent and thestudy was approved by the human research ethics commit-
tee at the Medical University of Silesia, Poland.
Selection of copy number variation polymorphisms
We evaluated all top genomic regions associated to blood
pressure phenotypes in the meta-analysis of GWA studies
by Ehret et al., [3] to see whether these regions contain
CNVs defined by the Database for Genomic Variation
(DGV, http://dgv.tcag.ca/dgv/app/home) [26], to which both
HapMap Project and 1000 Genomes Project are linked
(Additional file 1: Figure S1). This screening retrieved 4 lo-
cations with CNV loci (Table 1). Two of the locations con-
tained overlapping CNVs: esv27061 and esv2757747, and
dgv976e1, esv2656635, nsv908562 and dgv986e1 (Table 1).
Droplet digital polymerase chain reaction (ddPCR)
This study followed the Minimum Information for Publica-
tion of Quantitative Digital PCR Experiments guidelines
[27]. Four CNV assays were selected to genotype the 8
CNVs (Table 1). DNA samples, previously extracted from
whole blood [18-21], were quantified by spectrophotom-
etry. Given that one haploid human genome weighs 3.3 pg,
and approximately 10,000 copies of genome per reaction
are required for accurate ddPCR, we aimed to use 33 ng of
DNA per reaction. Prior to PCR, DNA was restriction
digested with either XbaI, EcoRI or EcoRV (Promega, Madi-
son, Wisconsin, USA, 1 unit per 1 μg of DNA) for 1 hour
at 37°C, followed by 20 minutes of heat inactivation at 65°C
in a PCR thermal cycler (BioRad, Hercules, California,
USA). PCR reactions were run in a total of 20 μl, contain-
ing 1 μl of the TaqMan assay (Life Technologies, Pleasan-
ton, California, USA) specific for the CNV of interest,
labelled with FAM dye, 1 μl of the copy number reference
assay for the TaqMan® Copy Number Reference Assay
Table 2 Characteristics of the extreme low and high
blood pressure subjects from the Victorian family
heart study
Characteristic Extreme low
BP (n = 92)
Extreme high
BP (n = 96)
P-value
SBP 98.6 ± 5.2 mmHg 165.9 ± 12.3 mmHg P < 0.001
DBP 64.3 ± 7.2 mmHg 94.4 ± 10.8 mmHg P < 0.001
Age 32.6 ± 14.5 years old 55.1 ± 8.3 years old P < 0.001
BMI 22.7 ± 3.2 kg.m−2 28.3 ± 4.5 kg.m−2 P < 0.001
Males (%) 47 (51.1%) 48 (50%) P = 0.88
Footnote: BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood
pressure; BMI, body mass index.
Values are represented are average ± standard deviation.
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USA), labelled with VIC dye, and 10 μl of the ddPCR™
Supermix for Probes (BioRad, Hercules, California, USA).
Cycling conditions were: initial 1 x 95°C for 10 min,
followed by 45 cycles of denaturation for 15 sec (ramp rate
at 2.5°C per sec), annealing-extension for 60 sec (ramp rate
at 2.5°C per sec), and finished with a heat kill at 98°C for
10 min. Denaturation and annealing-extension temperature
were optimised for each assay to improve distinction be-
tween positive and negative droplets (Additional file 1:
Table S1). Droplets were generated in a QX100 droplet
generator (BioRad, Hercules, California, USA). PCR was
run in a C1000 Touch PCR thermal cycler (BioRad,
Hercules, California, USA), and the results were read in a
QX100 droplet reader (BioRad, Hercules, California, USA).
In order to confirm the genotypes, 29 to 67% (depending
on the assay) of the samples were randomly repeated at
least twice in independent experiments.
Data analyses
ddPCR data were analysed using the QuantaSoft software
version 1.3.1.0, which measured the fraction of positive
droplets and calculated the amount of template per drop-
let based on a Poisson distribution, which precision esti-
mates a 95% confidence interval (CI) for each droplet.
Agreement with normal distribution was assessed by his-
tograms and estimation of skewness and kurtosis tests. A
logistic regression adjusting for age, BMI and sex was per-
formed to test the association between the CNVs and the
extreme high and low BP groups. Independent-sample
(two-tailed) Wilcoxon tests were used to identify if losses
or gains of CNVs were associated with SBP or DBP in each
group. Due to the small sample size, we did not adjust Wil-
coxon tests by age, sex or BMI. The CNVs nsv483076,
dgv976e1, esv2656635, nsv908562 and dgv986e1 were
mostly monomorphic, so no statistical analyses were per-
formed. Differences with P < 0.05 were considered statisti-
cally significant. Statistical package SPSS for Windows
(Release 17.0, 2008) was used in the statistical analysis.
Results
Mean SBP, DBP, age and BMI values were significantly
higher in extreme high when compared to low BP groups
(Table 2) [22]. The mean number of droplets analysed
(±standard error of measurement) for all the samples
ranged between 12729 ± 98 and 14725 ± 122 droplets, de-
pending on the assay. Samples in which number of copies
did not fall within the 95% Poisson CI for absolute number
of 1, 2 or 3 copies per diploid genome, and samples that
failed to amplify were repeated at least twice with consist-
ent results, and therefore were excluded from further ana-
lyses. One sample was excluded for CNVs esv27061 and
esv2757747 (0.5%), 7 for CNV nsv483076 (3.7%), 2 for the
CNVs dgv976e1, esv2656635, nsv908562 and dgv986e1(1%) and 14 for CNV dgv1306e1 (7.4%). We observed be-
tween 5466 ± 244 and 7872 ± 369 copies of DNA, depend-
ing on the assay. There was a high concordance between
replicates of the same sample (data not shown). Additional
file 1: Figure S2 shows an example of the quality of the copy
calls, reporting replicates with either 1, 2 or 3 copies.
There was a significantly higher prevalence of a deletion
in the overlapping CNVs esv27061 and esv2757747 on
chromosome 1 in individuals from extreme high BP (n =
12) than those from extreme low BP (n = 2) group (12.6%
vs. 2.2%, respectively; 95% confidence interval: 0.005–0.53;
β = 0.05; P = 0.013) after adjustment for BMI, age and sex
(Table 3 and Additional file 1: Figure S3). Within the
stratum of high extreme of SBP, there were no significant
difference in either SBP (+3.65 mmHg, P = 0.884) or DBP
(+0.53 mmHg, P = 0.263) between subjects with 1 or 2
copies of these CNVs (Figures 1A and B). In the extreme
low BP group the increase was of greater magnitude
(+6.03 mmHg SBP and 7.84 mmHg DBP), but the number
of subjects with the deletion was very small to perform
statistical analyses (n = 2).
Although there was no association between CNV
dgv1306e1 on chromosome 20p12.2 and the extreme high
and low BP (Additional file 1: Table S2), subjects from
the extreme low BP group with 3 copies had higher, but
non-significant, SBP (+2.4 mmHg, P = 0.069) and DBP
(+3.5 mmHg, P = 0.066) (Figure 1C and D). Subjects from
extreme high BP group with 3 copies of CNV dgv1306e1
had no significant difference in SBP (−4.5 mmHg, P =
0.308) than those with 2 copies, but they had significantly
lower DBP (−5.5 mmHg, P = 0.024) (Figure 1E and F).
No association was observed between the phenotypes
investigated and the CNV nsv483076 on chromosome
11p15.4, in which only one subject of the extreme high
BP group presented a duplication (Table 3).
The frequencies of the CNVs found in this study were
compared to the DGV data (Additional file 1: Table S2).
We observed that the presence of CNVs in the studies
described in the DGV was different from some of the
ones found in the present study. There was no gain
Table 3 Copy number variation (CNV) frequency in the extreme low and high cohort
CNV esv27061/esv2757747* CNV nsv483076 CNV dgv976e1/esv2656635/
nsv908562/dgv986e1
CNV dgv1306e1
Number of copies 1 copy (%) 2 copies (%) 2 copies (%) 3 copies (%) 2 copies (%) 2 copies (%) 3 copies (%)
Low BP: sample size (%) 2 (2.2) 90 (97.8) 90 (100) 0 91 (100) 63 (76.8) 19 (23.2)
High BP: sample size (%) 12 (12.6) 83 (87.4) 88 (98.9) 1 (1.1) 93 (100) 74 (82.2) 16 (17.8)
*P = 0.013 after adjustment for age, body mass index and sex.
Footnote: CNV, copy number variation; BP, blood pressure.
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esv2757747 for all participants we studied, while the re-
ported prevalence of gain in the DGV is 5.8% and 0.8%,
respectively (Additional file 1: Table S2). For the CNV
dgv1306e1, we observed a higher prevalence of vari-
ation of 20.3%, while the DGV reports only no variance.Figure 1 Systolic blood pressure (SBP) and diastolic blood pressure (D
for the CNVs esv27061 and esv2757747, there was no statistically significant diffe
According to the genotype for the CNV dgv1306e1, there was no difference in (
there was a significant decrease in DBP in the extreme high BP group (* indicate
were performed between subjects with losses or gains in copy number in eachAll subjects genotyped for the SRTB cohort had
2 copies of the CNVs esv27061 and esv2757747,
and therefore, we could not investigate if there
was a correlation between gene expression and the
deletion of a copy number in this region (data not
shown).BP) according to the genotype of CNVs. According to the genotype
rence in (A) SBP and (B) DBP in the extreme high blood pressure (BP) group.
C) SBP and (D) DBP in the extreme low blood pressure group, while (E)
s P= 0.024), and (F) no change in SBP. Independent-sample Wilcoxon tests
BP group. Graphs represent mean, error bars represent standard deviation.
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This study is the first, to our knowledge, to investigate copy
number variation in regions previously associated with BP
in genome-wide association studies by the use of absolute
DNA quantitation of droplet digital PCR and the ‘power of
extreme’ approach. Significantly higher frequency of a dele-
tion of the overlapping CNVs esv27061 and esv2757747 on
chromosome 1 was observed in those with extreme high
BP compared to low BP subjects. These CNVs are overlap-
ping with the SNP rs2932538, which was previously asso-
ciated with hypertension [3]. This indicates that CNVs in
this region could contribute to the previous positive asso-
ciation in the GWA meta-analysis. Although no associ-
ation was observed between the other three regions
studied, subjects from extreme high SBP with 3 copies of
the CNV dgv1306e1 in chromosome 20 had significantly
lower DBP. Surprisingly, the frequency of copy number in
our cohort of 184 European-descendent subjects was very
different than the one in the DGV, which suggests that the
data available in this database might be biased due to less
reliable measurement techniques.
Although we reported here that a deletion of the
CNVs esv27061 and esv2757747 was more prevalent in
hypertensive subjects, we could not find a significant as-
sociation with BP. This is likely a consequence of the
sampling design employed in this study. The selection of
subjects with extreme high and extreme low from a
population-based sample such as the VFHS offers power
in terms of the comparisons between, but not necessarily
within the extreme groups. Factors such as low preva-
lence of certain variants and high standard deviation in
the extreme high group militate against detection of ef-
fects within groups. Nevertheless, the observed BP differ-
ences with the deletion of the CNVs esv27061 and
esv2757747 were of consistent direction in both high and
low extreme groups. Also our data is consistent with the
GWA meta-analysis, in which the loci containing SNP
rs2932538 and CNVs esv27061/esv2757747 on chromo-
some 1 was associated with hypertension, but had a small
effect (β = 0.049) [3], very comparable to our result (β =
0.05). Other parallels between our CNV data and the GWA
meta-analysis were observed for the CNV dgv1306e1,
which showed a stronger association between the SNP
rs1327235 in chromosome 20 (where the CNV dgv1306e1
is located) and DBP (P = 1.4 × 10−15) than SBP (P = 1.9 ×
10−8) or hypertension (P = 4.6 × 10−4) [3].
The CNV esv2757747, located on 1p13.2-1p13.1, is
approximately 3.5 megabase pairs long (Mb) and en-
compasses 45 coding genes, including the one previ-
ously associated with BP coding moloney leukemia virus
10 (MOV10) [3], and several genes for long non-coding
RNAs (lncRNAs) of unknown function, but expressed
in relevant tissues such as heart and kidney (Additional
file 1: Table S3). LncRNAs, important for epigeneticregulation, are emerging as a new class of non-coding
RNAs possibly involved in cardiovascular disease [28].
Amongst the genes in this region is the one coding for the
nerve growth factor (NGF). This gene been previously im-
plicated in BP regulation in the spontaneously hypertensive
rats (SHR), the most studied model of hypertension [29,30].
The esv27061 variant is a smaller CNV of 553,635 bp
on chromosome 1p13.2, which encompass 9 genes, in-
cluding MOV10, and a gene for a microRNA, miR-4256
(Additional file 1: Table S3). Besides MOV10, none of
them have been previously associated with BP or hyperten-
sion. The CNV dgv1306e1, of 224,588 bp on 20p12.2, ini-
tially contained the jagged 1 gene (JAG1) when the meta-
analysis was published [3]. In the newest human genome
browser, GRCh37/hg19, JAG1 no longer maps within CNV
dgv1306e1, while one new transcript (C20orf187) and sev-
eral new lncRNAs, with unknown roles but transcribed in
relevant tissues to BP regulation such as kidney, have been
described in this region (Additional file 1: Table S3).
The combined usage of comparative genomic hybridisa-
tion (CGH) arrays and qPCR identified 16 CNVs associ-
ated with BP distributed across 8 chromosomes in the
SHR [31]. The expression of several genes within theses
CNVs were validated in kidney, heart and spleen [31]. Of
particular interest was the gene coding for EGL nine
homolog 1 (Egln1), which is located in an orthologous re-
gion in humans and was shown in a large F2 cross to be
associated with BP [31]. No validation, however, has been
done in humans so far. A study which sequenced the
whole-genome of the SHR identified 588 CNVs overlap-
ping with 688 genes [32], but gene expression was not in-
vestigated. There are few studies aimed at finding CNVs
that could contribute to the pathophysiology of essential
hypertension in humans. The first GWA study for CNVs
in essential hypertension, which designed their own arrays
using the Agilent CGH platform, analysed ~2,000 hyper-
tensive subjects with British ancestry and ~3,000 controls,
and found no association between any CNVs and hyper-
tension [9]. Interestingly, from the initial 11,541 loci tar-
geted, only 3,432 CNVs (31.6%) passed quality control
filters indicating the difficulty in accurate quantitation.
Another study which used a similar population size con-
verted data from SNP-arrays to CNVs based on allele in-
tensity, and found 7 CNVs associated with hypertension
[33]. None of these regions, however, are the same ones
identified in this study or in the GWA meta-analysis [3].
In order to find the functional role for the CNVs associ-
ated with hypertension in this study, we genotyped 40
Polish subjects with normal or high BP, for which we have
matching kidney samples. All subjects, however, had 2
copies of the CNVs esv27061 and esv2757747, and there-
fore, we could not investigate if there was a correlation be-
tween gene expression and the deletion of a copy number
in this region (data not shown). The lack of variability in
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background of the two cohorts (white-Australian vs.
Polish), the small sample size of the Polish cohort ana-
lysed, or by the enrichment for rare variants in the ex-
treme BP groups [34].
The frequency of loss or gain of copy number described
in the DGV (UCSC Genome Browser and GRCh37/hg19
assembly, search performed on 29 May 2014) is presented
in Additional file 1: Table S2 [4,6,35]. For the CNVs
esv27061 and esv2757747, we did not observe any gain in
copy number for all subjects genotyped. Furthermore, the
higher prevalence of the CNV dgv1306e1 in our cohort
(20.3%) compared to the DGV (0%) could be a result of
the enrichment for rare variants by the use of the ‘power
of extreme’ approach for high and low BP used in the
present study [34], or high diversity between different
populations for this and CNV dgv1306e1 loci. The studies
that reported these first frequencies, however, used CGH
arrays and small sample sizes (n = 40, [4] n = 55 [4] and
n = 270 [6]) compared to more recent whole-genome
studies. CGH arrays are based on hybridisation of labelled
DNA to genomic clones, together with the hybridisation
of a reference sample; therefore it is a relative measure-
ment. Literature suggests <70% reproducibility in replicate
experiments between platforms and algorithms for CGH
and SNP arrays used for CNV detection [36]. The 1000
Genomes Project, which used a combination of exome
sequencing and low-coverage whole-genome [37], will
hopefully be able to rectify the frequency of CNVs
reported in databases.
Technical difficulties and inaccuracy have been re-
ported in the measurement of CNVs by qPCR [10]. For
single CNV investigations, studies comparing qPCR and
dPCR have proven the superiority of dPCR in accuracy
and reproducibility [14,15]. One of the reasons is the
number of replicates necessary for accurate qPCR results.
For example, at least 8 replicates are needed when using
qPCR to detect ratios of relative quantity greater than 1.25
with 95% power [15]. Some samples were excluded be-
cause an absolute 1, 2 or 3 copy number (0.5-7.4% de-
pending on the assay) was not obtained. This may be
caused by mosaicism in the population, in accordance
with recent findings by another group using ddPCR [38],
or degradation of this region in some DNA copies.
We have to acknowledge several limitations of the
present study. One limitation relates to the absence of a
clear agreement regarding quality control for results ob-
tained by the new technology of ddPCR. The technique is
labour intensive and each sample needs to be analysed in-
dividually. The small sample sizes would normally limit
power for detection of genetic association. However, the
use of the extreme phenotype approach enhances the
power to detect association [16,17,22,39,40]. Previous cal-
culations [39] of our effective sample size estimated powerto be equivalent to an analysis of 1714 unselected subjects
[20]. One consideration about the use of extreme pheno-
types, however, is that it could select for rare syndromes
and associated diseases, therefore decreasing the physio-
logical relevance of the associations. To minimise this pos-
sible issue, subjects with other forms of hypertension than
essential hypertension were excluded increasing the gen-
etic power of our analyses. Finally, we did not validate the
findings in a larger population because these regions have
been previously associated with BP and hypertension in
over 200,000 subjects [3].
Conclusions
Our results show an association between the CNVs
esv27061 and esv2757747 and extreme high BP subjects,
and the CNV dgv1306e1 and DBP in hypertensive subjects
by the use of the recently available and highly precise ddPCR
in an extreme phenotype study. The results are in accord-
ance to largest GWA meta-analysis, and together they sug-
gest that CNVs in at least one of these regions could be an
underlying factor to the initial association. The function of
these CNVs in BP regulation, however, needs to be clarified.
Additional file
Additional file 1: Online Data Supplement.
Abbreviations
BMI: Body mass index; BP: Blood pressure; CNV: Copy number variation;
DBP: Diastolic blood pressure; ddPCR: Droplet digital polymerase chain
reaction; DGV: Database for Genomic Variation; DNA: Deoxyribonucleic acid;
GWA: Genome-wide association; PCR: Polymerase chain reaction; qPCR:
Real-time polymerase chain reaction; RNA: Ribonucleic acid; SBP: Systolic
blood pressure; SNP: Single nucleotide polymorphism; SRTB: Silesian Renal
Tissue Bank; VFHS: Victorian Family Heart Study.
Competing interests
The authors have declared no conflict of interest.
Authors’ contributions
FZM participated in the study design, carried out the molecular genetic
studies and statistical analyses, and drafted most of the manuscript. PRP
participated in the ddPCR experiments. LBP and KRE participated in the
design of the ddPCR experiments. KS participated in the design of the study
and supervised statistical analyses. MT participated in the design of the
study. SBH and FJC conceived the study, participated in its design and
coordination. All authors helped draft the manuscript and read and
approved the final version.
Acknowledgements
We would like to thank BioRad for the support to troubleshoot the ddPCR
data. This work was supported by grants from the National Health & Medical
Research Council of Australia (NHMRC) (project grant 526662) and the
Federation University Australia ‘Self-sustaining Regions Research and
Innovation Initiative’, an Australian Government Collaborative Research
Network (CRN). F.Z.M. is supported by NHMRC (APP1052659) and National
Heart Foundation (PF12M6785) co-shared Early Career Fellowships. P.R.P. is
supported by a Robert HT Smith Fellowship from the Federation University
Australia. M.T. is supported by British Heart Foundation. Work undertaken at
the National Measurement Institute (L.B.P. and K.R.E.) was supported by the
National Enabling Technology Strategy provided by the Commonwealth
Government of Australia.
Marques et al. BMC Medical Genomics 2014, 7:44 Page 7 of 8
http://www.biomedcentral.com/1755-8794/7/44Author details
1Faculty of Science, Federation University Australia, Y Building, University
Drive, Mt Helen, 3350, Ballarat, VIC, Australia. 2National Measurement Institute,
Sydney, NSW, Australia. 3Department of Physiology, University of Melbourne,
Melbourne, VIC, Australia. 4Department of Cardiovascular Science, University
of Leicester, Leicester, UK.
Received: 20 January 2014 Accepted: 9 July 2014
Published: 15 July 2014References
1. Charchar F, Zimmerli L, Tomaszewski M: The pressure of finding human
hypertension genes: new tools, old dilemmas. J Hum Hypertens 2008,
22(12):821–828.
2. Munroe PB, Barnes MR, Caulfield MJ: Advances in blood pressure
genomics. Circ Res 2013, 112(10):1365–1379.
3. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV,
Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF,
Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH,
Aulchenko Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang
F, Lucas G, Hicks AA, Jackson AU, et al: Genetic variants in novel
pathways influence blood pressure and cardiovascular disease risk.
Nature 2011, 478(7367):103–109.
4. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW,
Lee C: Detection of large-scale variation in the human genome.
Nat Genet 2004, 36(9):949–951.
5. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM,
Clark RA, Schwartz S, Segraves R, Oseroff VV, Albertson DG, Pinkel D, Eichler EE:
Segmental duplications and copy-number variation in the human genome.
Am J Hum Genet 2005, 77(1):78–88.
6. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H,
Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR,
Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR,
Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda
J, Valsesia A, Woodwark C, Yang F, et al: Global variation in copy number in
the human genome. Nature 2006, 444(7118):444–454.
7. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa
H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A,
Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M: Large-scale copy
number polymorphism in the human genome. Science 2004,
305(5683):525–528.
8. Feuk L, Carson AR, Scherer SW: Structural variation in the human genome.
Nat Rev Genet 2006, 7(2):85–97.
9. Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, Vukcevic D,
Barnes C, Conrad DF, Giannoulatou E, Holmes C, Marchini JL, Stirrups K, Tobin
MD, Wain LV, Yau C, Aerts J, Ahmad T, Andrews TD, Arbury H, Attwood A,
Auton A, Ball SG, Balmforth AJ, Barrett JC, Barroso I, Barton A, Bennett AJ,
Bhaskar S, Blaszczyk K: Genome-wide association study of CNVs in 16,000
cases of eight common diseases and 3,000 shared controls. Nature 2010,
464(7289):713–720.
10. Aldhous MC, Abu Bakar S, Prescott NJ, Palla R, Soo K, Mansfield JC, Mathew
CG, Satsangi J, Armour JA: Measurement methods and accuracy in copy
number variation: failure to replicate associations of β-defensin copy
number with Crohn’s disease. Hum Mol Genet 2010, 19(24):4930–4938.
11. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA: Quantitation
of targets for PCR by use of limiting dilution. Biotechniques 1992,
13(3):444–449.
12. Vogelstein B, Kinzler KW: Digital PCR. Proc Natl Acad Sci U S A 1999,
96(16):9236–9241.
13. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz
AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR,
Petersen JF, Wyatt PW, Steenblock ER, Shah PH, Bousse LJ, Troup CB, Mellen
JC, Wittmann DK, Erndt NG, Cauley TH, Koehler RT, So AP, Dube S, Rose KA,
Montesclaros L, Wang S, Stumbo DP, Hodges SP: High-throughput droplet
digital PCR system for absolute quantitation of DNA copy number.
Anal Chem 2011, 83(22):8604–8610.
14. Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, Jones RC, Livak KJ:
Taking qPCR to a higher level: analysis of CNV reveals the power of high
throughput qPCR to enhance quantitative resolution. Methods 2010,
50(4):271–276.15. Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, Foy CA, Scott DJ:
Comparison of microfluidic digital PCR and conventional quantitative PCR
for measuring copy number variation. Nucleic Acids Res 2012, 40(11):e82.
16. Froguel P, Blakemore AI: The power of the extreme in elucidating obesity.
N Engl J Med 2008, 359(9):891–893.
17. Walters RG, Jacquemont S, Valsesia A, De Smith AJ, Martinet D, Andersson J,
Falchi M, Chen F, Andrieux J, Lobbens S, Delobel B, Stutzmann F, El-Sayed
Moustafa JS, Chevre JC, Lecoeur C, Vatin V, Bouquillon S, Buxton JL, Boute
O, Holder-Espinasse M, Cuisset JM, Lemaitre MP, Ambresin AE, Brioschi A,
Gaillard M, Giusti V, Fellmann F, Ferrarini A, Hadjikhani N, Campion D, et al:
A new highly penetrant form of obesity due to deletions on
chromosome 16p11.2. Nature 2010, 463(7281):671–675.
18. Harrap SB, Wong ZY, Stebbing M, Lamantia A, Bahlo M: Blood pressure
QTLs identified by genome-wide linkage analysis and dependence on
associated phenotypes. Physiol Genomics 2002, 8(2):99–105.
19. Ellis JA, Stebbing M, Harrap SB: Male pattern baldness is not associated
with established cardiovascular risk factors in the general population.
Clin Sci (Lond) 2001, 100(4):401–404.
20. Ellis JA, Wong ZY, Stebbing M, Harrap SB: Sex, genes and blood pressure.
Clin Exp Pharmacol Physiol 2001, 28(12):1053–1055.
21. Harrap SB, Stebbing M, Hopper JL, Hoang HN, Giles GG: Familial patterns
of covariation for cardiovascular risk factors in adults: the Victorian
Family Heart Study. Am J Epidemiol 2000, 152(8):704–715.
22. Busst CJ, Scurrah KJ, Ellis JA, Harrap SB: Selective genotyping reveals
association between the epithelial sodium channel ɣ-subunit and
systolic blood pressure. Hypertension 2007, 50(4):672–678.
23. Vincent M, Boussairi EH, Cartier R, Lo M, Sassolas A, Cerutti C, Barres C,
Gustin MP, Cuisinaud G, Samani NJ: High blood pressure and metabolic
disorders are associated in the Lyon hypertensive rat. J Hypertens 1993,
11(11):1179–1185.
24. Tomaszewski M, Charchar FJ, Nelson CP, Barnes T, Denniff M, Kaiser M,
Debiec R, Christofidou P, Rafelt S, van der Harst P, Wang WY, Maric C,
Zukowska-Szczechowska E, Samani NJ: Pathway analysis shows association
between FGFBP1 and hypertension. J Am Soc Nephrol 2011, 22(5):947–955.
25. Marques FZ, Campain AE, Tomaszewski M, Yang YHJ, Zukowska-
Sczechowska E, Charchar FJ, Morris BJ: Gene expression profiling reveals
renin mRNA overexpression in human hypertensive kidneys and a role
for microRNAs. Hypertension 2011, 58:1093–1098.
26. MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW: The Database of
Genomic Variants: a curated collection of structural variation in the
human genome. Nucleic Acids Res 2014, 42(Database issue):D986–D992.
27. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, Hellemans J,
Kubista M, Mueller RD, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J,
Wittwer CT, Bustin SA: The Digital MIQE Guidelines: Minimum Information
for Publication of Quantitative Digital PCR Experiments. Clin Chem 2013,
59(6):892–902.
28. Schonrock N, Harvey RP, Mattick JS: Long noncoding RNAs in cardiac
development and pathophysiology. Circ Res 2012, 111(10):1349–1362.
29. Charchar FJ, Kapuscinski MK, Harrap SB: Nerve growth factor gene locus
explains elevated renal nerve growth factor mRNA in young
spontaneously hypertensive rats. Hypertension 1998, 32(4):705–709.
30. Nemoto K, Sekimoto M, Fukamachi K, Kageyama H, Degawa M, Hamadai M,
Hendley ED, Macrae IM, Clark JS, Dominiczak AF, Ueyama T: No
involvement of the nerve growth factor gene locus in hypertension in
spontaneously hypertensive rats. Hypertens Res 2005, 28(2):155–163.
31. Charchar FJ, Kaiser M, Bingham AJ, Fotinatos N, Ahmady F, Tomaszewski M,
Samani NJ: Whole genome survey of copy number variation in the
spontaneously hypertensive rat: relationship to quantitative trait loci,
gene expression, and blood pressure. Hypertension 2010, 55(5):1231–1238.
32. Atanur SS, Birol I, Guryev V, Hirst M, Hummel O, Morrissey C, Behmoaras J,
Fernandez-Suarez XM, Johnson MD, McLaren WM, Patone G, Petretto E,
Plessy C, Rockland KS, Rockland C, Saar K, Zhao Y, Carninci P, Flicek P, Kurtz
T, Cuppen E, Pravenec M, Hubner N, Jones SJ, Birney E, Aitman TJ: The
genome sequence of the spontaneously hypertensive rat: analysis and
functional significance. Genome Res 2010, 20(6):791–803.
33. Chen X, Li X, Wang P, Liu Y, Zhang Z, Zhao G, Xu H, Zhu J, Qin X, Chen S,
Hu L, Kong X: Novel association strategy with copy number variation for
identifying new risk loci of human diseases. PLoS One 2010, 5(8):e12185.
34. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ,
McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE,
Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS,
Marques et al. BMC Medical Genomics 2014, 7:44 Page 8 of 8
http://www.biomedcentral.com/1755-8794/7/44Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA,
Visscher PM: Finding the missing heritability of complex diseases.
Nature 2009, 461(7265):747–753.
35. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J,
Andrews TD, Barnes C, Campbell P, Fitzgerald T, Hu M, Ihm CH, Kristiansson K,
Macarthur DG, Macdonald JR, Onyiah I, Pang AW, Robson S, Stirrups K, Valsesia
A, Walter K, Wei J, Tyler-Smith C, Carter NP, Lee C, Scherer SW, Hurles ME:
Origins and functional impact of copy number variation in the human
genome. Nature 2010, 464(7289):704–712.
36. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T, Lionel AC,
Thiruvahindrapuram B, Macdonald JR, Mills R, Prasad A, Noonan K, Gribble S,
Prigmore E, Donahoe PK, Smith RS, Park JH, Hurles ME, Carter NP, Lee C,
Scherer SW, Feuk L: Comprehensive assessment of array-based platforms
and calling algorithms for detection of copy number variants.
Nat Biotechnol 2011, 29(6):512–520.
37. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE,
Kang HM, Marth GT, McVean GA: An integrated map of genetic variation
from 1,092 human genomes. Nature 2012, 491(7422):56–65.
38. Abyzov A, Mariani J, Palejev D, Zhang Y, Haney MS, Tomasini L, Ferrandino AF,
Rosenberg Belmaker LA, Szekely A, Wilson M, Kocabas A, Calixto NE,
Grigorenko EL, Huttner A, Chawarska K, Weissman S, Urban AE, Gerstein M,
Vaccarino FM: Somatic copy number mosaicism in human skin revealed by
induced pluripotent stem cells. Nature 2012, 492(7429):438–442.
39. Donner A, Klar N: Design and analysis of cluster randomization trials in health
research. New York, NY: Oxford University Press; 2000.
40. Van Gestel S, Houwing-Duistermaat JJ, Adolfsson R, van Duijn CM, Van
Broeckhoven C: Power of selective genotyping in genetic association
analyses of quantitative traits. Behav Genet 2000, 30(2):141–146.
doi:10.1186/1755-8794-7-44
Cite this article as: Marques et al.: Measurement of absolute copy
number variation reveals association with essential hypertension. BMC
Medical Genomics 2014 7:44.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
